DNA vaccine encoding ESAT-6 enhances the protective efficacy of BCG against Mycobacterium tuberculosis infection in mice

Scandinavian Journal of Immunology

Volumn 66, Issue 5, 2007, Pages 523-528

  Fan, X ^a   Gao, Q ^a   Fu, R ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; DNA VACCINE; EARLY SECRETORY ANTIGENIC TARGET 6; EOSIN; GAMMA INTERFERON; HEMATOXYLIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAGG ALBINO MOUSE; BCG VACCINATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; DNA IMMUNIZATION; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; INFECTION PREVENTION; LUNG; MONOTHERAPY; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SPLEEN; SPLEEN CELL; TUBERCULOSIS;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; INTERFERON TYPE II; LUNG; MICE; MYCOBACTERIUM BOVIS; SPLEEN; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINES, DNA;

EID: 35348937137     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2007.02006.x     Document Type: Article

References (17)

1. Fine PEM, Carneiro IAM, Milstien JB, Clements CJ. Issues Relating to the Use of BCG in Immunization Programmes. Geneva : WHO, 1999.
2. Fine PEM. Variation in protection by BCG: implication of and for heterologous immunity. Lancet 1995 346 : 1339 45.
3. Andersen P, Doherty MT. The success and failure of BCG - implications for a novel tuberculosis vaccine. Nature Rev Microbiol 2005 3 : 656 62.
4. Behr MA, Wilson MA, Gill WP et al. Comparative genomics of BCG vaccines by whole genome DNA microarray. Science 1999 284 : 1520 3.
5. + T lymphocytes specific for Mycobacterium tuberculosis. Proc Natl Acad Sci USA 1998 95 : 270 5.
6. Anderson P, Anderson AB, Sorensen AL, Nagai S. Recall of long-lived immunity to Mycobacterium tuberculosis infection in mice. J Immunol 1995 154 : 3359 72.
7. Brandt L, Elhay M, Rosenkrands I, Lindblad EB, Andersen P. ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect Immun 2000 68 : 791 5.
8. Pym AS, Brodin P, Majlessi L et al. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nature Med 2003 9 : 533 9.
9. Fan X, Yu T, Gao Q, Yao W. Immunological properties of recombinant Mycobacterium bovis Bacillus Calmette-Guérin strain expressing fusion protein IL-2-ESAT-6. Acta Biochim Biophys Sin 2006 38 : 683 90.
10. Pym AS, Brodin P, Brosch R, Huerre M, Cole ST. Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti. Mol Microbiol 2002 46 : 709 17.
11. Huygen K, Content J, Denis O et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med 1996 2 : 893 8.
12. Kamath AT, Feng CG, Macdonald M. Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis. Infect Immun 1999 67 : 1702 7.
13. Romano M, Roupie V, Wang XM et al. Immunogenicity and protective efficacy of tuberculosis DNA vaccines combining mycolyl-transferase Ag85A and phosphate transport receptor PstS-3. Immunology 2006 118 : 321 32.
14. Fan X, Gao Q, Fu R. Differential immunogenicity and protective efficacy of DNA vaccines expressing proteins of Mycobacterium tuberculosis in a mouse model. Microbiol Res 2007 doi :.
15. Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S. Recombinant BCG vaccines expressing the Mycobacterium tuberculosis 30 kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci USA 2000 97 : 13853 8.
16. Feng CG, Palendira U, Demangel C, Spratt JM, Malin AS, Britton WJ. Priming by DNA immunization augments protective efficacy of Mycobacterium bovis Bacille Calmette-Guerin against tuberculosis. Infect Immun 2001 69 : 4174 6.
17. Kaufmann SHE. How can immunology contribute to the control of tuberculosis? Nature Rev Immunol 2001 1 : 20 30.